RESUMO
Sepsis is a severe inflammatory disease characterized by cytokine storm, often accompanied by disseminated intravascular coagulation (DIC). PANoptosis is a novel form of cell death triggered by cytokine storms, characterized by a cascade reaction of pyroptosis, apoptosis, and necroptosis. It exists in septic platelets and is closely associated with the onset and progression of DIC. However, there remains an unmet need for drugs targeting PANoptosis. The anti-PANoptosis effect of myricetin was predicted using network pharmacology and confirmed through molecular docking. In vitro platelet activation models demonstrated that myricetin significantly attenuated platelet particle release, integrin activation, adhesion, spreading, clot retraction, and aggregation. Moreover, in a sepsis model, myricetin reduced inflammatory infiltration in lung tissue and platelet activation while improving DIC. Additionally, whole blood sequencing samples from sepsis patients and healthy individuals were analyzed to elucidate the up-regulation of the PANoptosis targets. Our findings demonstrate the inhibitory effect of myricetin on septic platelet PANoptosis, indicating its potential as a novel anti-cellular PANoptosis candidate and therapeutic agent for septic DIC. Furthermore, our study establishes a foundation for utilizing network pharmacology in the discovery of new drugs to treat various diseases.
Assuntos
Plaquetas , Coagulação Intravascular Disseminada , Flavonoides , Sepse , Flavonoides/farmacologia , Flavonoides/uso terapêutico , Sepse/tratamento farmacológico , Sepse/sangue , Humanos , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Coagulação Intravascular Disseminada/tratamento farmacológico , Coagulação Intravascular Disseminada/etiologia , Coagulação Intravascular Disseminada/patologia , Coagulação Intravascular Disseminada/sangue , Animais , Masculino , Simulação de Acoplamento Molecular , Ativação Plaquetária/efeitos dos fármacos , Camundongos Endogâmicos C57BL , Camundongos , Piroptose/efeitos dos fármacosRESUMO
BACKGROUND: Emicizumab (Emi) is used as haemostatic prophylaxis for patients with haemophilia A (PwHA). Disseminated intravascular coagulation (DIC) is a condition characterized by persistent systemic activation of coagulation, but there is yet no information on coagulation and fibrinolysis potentials in Emi-treated PwHA with DIC. AIM: To examine the effect of Emi on coagulation and fibrinolysis potentials in HA-model DIC plasmas. METHODS: Plasma from a patient with sepsis-DIC (seven patients) was treated with anti-factor (F)VIII monoclonal antibody (HA-model DIC plasma) and incubated with Emi (50 µg/mL). The plasma was then assessed using clot-fibrinolysis waveform analysis (CFWA). Coagulation and fibrinolysis parameters were expressed as ratios relative to normal plasma (|min1|-ratio and |FL-min1|-ratio, respectively). PATIENTS AND RESULTS: In case 1, coagulant potential was slightly high and fibrinolytic potential was extremely low, presenting a coagulant-dominant state (|min1|-ratio/|FL-min1|-ratio: 1.1/.38). In cases 2-5, fibrinolytic potential was not suppressed, but there were marked hypercoagulant potentials, indicating relative coagulant-dominant states. In case 6, coagulant and fibrinolytic potentials were increased but well balanced (|min1|-ratio/|FL-min1|-ratio: 1.38/1.28). In case 7, both potentials were severely deteriorated in not only CFWA but also the thrombin/plasmin generation assay. The addition of Emi into the HA-model DIC plasmas increased |min1|-ratio values in all cases, but the coagulant potentials did not exceed the initial ones (DIC plasma before treatment with anti-FVIII antibody). CONCLUSIONS: The presence of Emi in the HA-model DIC plasma improved coagulation potentials, but did not increase coagulation potentials beyond those of DIC plasma in non-HA states.
Assuntos
Anticorpos Biespecíficos , Anticorpos Monoclonais Humanizados , Coagulação Sanguínea , Coagulação Intravascular Disseminada , Fibrinólise , Feminino , Humanos , Masculino , Anticorpos Biespecíficos/uso terapêutico , Anticorpos Biespecíficos/farmacologia , Anticorpos Monoclonais Humanizados/uso terapêutico , Anticorpos Monoclonais Humanizados/farmacologia , Coagulação Sanguínea/efeitos dos fármacos , Coagulação Intravascular Disseminada/tratamento farmacológico , Coagulação Intravascular Disseminada/etiologia , Coagulação Intravascular Disseminada/sangue , Fator VIII/uso terapêutico , Fator VIII/farmacologia , Fator VIII/imunologia , Fibrinólise/efeitos dos fármacosRESUMO
BACKGROUND: D-dimer, a specific product of cross-linked fibrin degradation, is of great clinical value in the early diagnosis of thrombotic diseases and in monitoring the efficacy of thrombolysis; therefore, the accuracy of D-dimer test results is crucial. METHODS: This article reports a case of a patient with disseminated intravascular coagulation (DIC) who experienced a false decrease in D-dimer due to the hook effect. RESULTS: The three D-dimer test results for DIC patients were 1.09 mg/L, 0.93 mg/L, and 1.43 mg/L. After sample dilution, the results were: first time (1:128) 842.24 mg/L, second time (1:128) 1,505.28 mg/L, third time (1:32) 415.68 mg/L. There was a significant difference in the three test results before and after dilution, because the D-dimer concentration was too high, exceeding the detection range and causing the hook effect, which falsely lowered the D-dimer value. CONCLUSIONS: When the D-dimer value of DIC patients does not match the clinical situation, the possibility of the hook effect should be considered, and the false decrease can be ruled out by the sample dilution method. In this way, accurate clinical results can be obtained to avoid delaying the diagnosis and treatment of DIC patients.
Assuntos
Coagulação Intravascular Disseminada , Produtos de Degradação da Fibrina e do Fibrinogênio , Humanos , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/diagnóstico , Masculino , Feminino , Reações Falso-Positivas , Pessoa de Meia-Idade , Idoso , Reações Falso-NegativasRESUMO
PURPOSE: To develop a new cost-effective marker named creatinine-fibrinogen ratio (CFR) for the prediction of composite adverse outcomes (CAO) in placental abruption cases. METHODS: A total of 109 placental abruption patients (30 with adverse outcomes, 79 without adverse outcomes) were enrolled in this retrospective cohort study. Patients with at least one of the features listed below were included in the abruption with CAO group: requirement of blood product transfusion (erythrocyte suspension, fresh frozen plasma, pooled thrombocyte, thrombocyte apheresis), development of acute kidney injury or disseminated intravascular coagulation, and need for intensive care unit. Laboratory parameters and CFR values at admission to the hospital were compared between the two groups. RESULTS: Higher creatinine and lower fibrinogen levels were found in the CAO group (p = 0.007 and p < 0.001 respectively). The CFR value of the CAO group was significantly higher (p < 0.001). In the ROC curve analysis performed to investigate the value of CFR in CAO prediction, the area under the curve (AUC) was calculated as 0,802 (95% CI 0.709-0.895, 77% sensitivity, 65% specificity). CONCLUSION: CFR seems to be a practical marker for the prediction of CAOs in pregnant women with ablatio placenta.
Assuntos
Descolamento Prematuro da Placenta , Biomarcadores , Creatinina , Fibrinogênio , Humanos , Feminino , Gravidez , Descolamento Prematuro da Placenta/sangue , Descolamento Prematuro da Placenta/diagnóstico , Estudos Retrospectivos , Adulto , Biomarcadores/sangue , Creatinina/sangue , Fibrinogênio/análise , Injúria Renal Aguda/sangue , Injúria Renal Aguda/diagnóstico , Curva ROC , Valor Preditivo dos Testes , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/diagnóstico , Coagulação Intravascular Disseminada/etiologia , Transfusão de Sangue , Adulto JovemAssuntos
Coagulação Intravascular Disseminada , Fibrinólise , Hemostasia , Humanos , Fibrinólise/fisiologia , Fibrinólise/efeitos dos fármacos , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/diagnóstico , Coagulação Intravascular Disseminada/fisiopatologia , Hemostasia/fisiologiaRESUMO
Since July 2022, obstetrical disseminated intravascular coagulation (DIC) in Japan has been diagnosed based on the new criteria (tentative version), which assesses the main underlying disease, fibrinogen level, and fibrin/fibrinogen degradation products or D-dimer level. In June 2024, the tentative version underwent minor revision and the final version was released. The previous Japanese criteria assessed underlying disease, clinical symptoms, and various laboratory findings. This study aimed to prove the effectiveness, reliability, and validity of the new criteria (final version). We analyzed 212 women with singleton pregnancies who delivered after 22 gestational weeks and experienced blood loss ≥ 1000 mL during vaginal delivery or ≥ 2000 mL during cesarean section. Those with missing laboratory findings before receiving blood transfusion at delivery were excluded. In the obstetrical DIC group, the frequency of fibrinogen levels < 150 mg/dL was significantly higher than in the control group (90% vs. 5%, p < 0.0001), as was the frequency of scores ≥ 8 according to the previous Japanese criteria (100% vs. 10%, p < 0.0001). Cronbach alpha was 0.757 and Spearman's rank-order correlation was 0.558 between the new and previous criteria. In conclusion, we proved the effectiveness, reliability, and validity of the Japanese new criteria (final version) to diagnose obstetrical DIC.
Assuntos
Coagulação Intravascular Disseminada , Produtos de Degradação da Fibrina e do Fibrinogênio , Humanos , Coagulação Intravascular Disseminada/diagnóstico , Coagulação Intravascular Disseminada/sangue , Feminino , Gravidez , Japão , Adulto , Reprodutibilidade dos Testes , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrinogênio/análise , Fibrinogênio/metabolismo , Complicações Hematológicas na Gravidez/diagnóstico , Complicações Hematológicas na Gravidez/sangue , Cesárea , População do Leste AsiáticoRESUMO
Coagulopathy, microvascular alterations and concomitant organ dysfunctions are hallmarks of sepsis. Attempts to attenuate coagulation activation with an inhibitor of tissue factor (TF), i.e. tissue factor pathway inhibitor (TFPI), revealed no survival benefit in a heterogenous group of sepsis patients, but a potential survival benefit in patients with an international normalized ratio (INR) < 1.2. Since an increased TF/TFPI ratio determines the procoagulant activity specifically on microvascular endothelial cells in vitro, we investigated whether TF/TFPI ratio in blood is associated with INR alterations, organ dysfunctions, disseminated intravascular coagulation (DIC) and outcome in septic shock. Twenty-nine healthy controls (HC) and 89 patients with septic shock admitted to a tertiary ICU were analyzed. TF and TFPI in blood was analyzed and related to organ dysfunctions, DIC and mortality. Patients with septic shock had 1.6-fold higher levels of TF and 2.9-fold higher levels of TFPI than HC. TF/TFPI ratio was lower in septic shock compared to HC (0.003 (0.002-0.005) vs. 0.006 (0.005-0.008), p < 0.001). Non-survivors had higher TFPI levels compared to survivors (43038 (29354-54023) vs. 28041 (21675-46582) pg/ml, p = 0.011). High TFPI levels were associated with acute kidney injury, liver dysfunction, DIC and disease severity. There was a positive association between TF/TFPI ratio and troponin T (b = 0.531 (0.309-0.754), p < 0.001). A high TF/TFPI ratio is exclusively associated with myocardial injury but not with other organ dysfunctions. Systemic TFPI levels seem to reflect disease severity. These findings point towards a pathophysiologic role of TF/TFPI in sepsis-induced myocardial injury.
Assuntos
Lipoproteínas , Choque Séptico , Tromboplastina , Humanos , Choque Séptico/sangue , Choque Séptico/metabolismo , Tromboplastina/metabolismo , Masculino , Feminino , Lipoproteínas/sangue , Lipoproteínas/metabolismo , Pessoa de Meia-Idade , Idoso , Insuficiência de Múltiplos Órgãos/sangue , Insuficiência de Múltiplos Órgãos/etiologia , Coagulação Intravascular Disseminada/sangue , Estudos de Casos e Controles , Adulto , Biomarcadores/sangueRESUMO
BACKGROUND: Disseminated intravascular coagulation (DIC) is a common complication of all leukemia subtypes, but it is an especially prominent feature of Acute Myeloid Leukemias (AML). DIC complicating AML can lead to a variety of complications, however, its association with acute cardiovascular complications has not been reported before. METHODS: National Inpatient Sample Database was used to procure individuals with AML, and baseline demographics and comorbidities were collected using ICD-10-DM codes. Patients were stratified into those with and without DIC. Greedy propensity matching using R was performed to match the two cohorts in 1:1 ratio on age, gender, and fifteen other baseline comorbidities. Univariate analysis pre and post-match along with binary logistic regression analysis post-match were used to analyze outcomes. RESULTS: Out of a total of 37,344 patients with AML, 996 had DIC. DIC patients were younger, predominantly males, and had lower prevalence of baseline cardiovascular comorbidities. DIC patients had statistically significant higher mortality (30.2 % vs 7.8 %), acute myocardial infarction (5.1 % vs 1.8 %), acute pulmonary edema (2.3 % vs 0.7 %), cardiac arrest (6.4 % vs 0.9 %), and acute DVT/PE (6.6 % vs 2.7 %). Logistic regression model after matching showed similar outcomes along with significantly higher rates of acute heart failure in DIC patients. CONCLUSION: These findings highlight the importance of close cardiovascular monitoring and prompt recognition of complications in AML patients with DIC. The underlying mechanisms involve a complex interplay of procoagulant factors, cytokine release, and endothelial dysfunction. Further studies are needed to develop targeted interventions for prevention and management of these complications.
Assuntos
Coagulação Intravascular Disseminada , Leucemia Mieloide Aguda , Humanos , Masculino , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/etiologia , Coagulação Intravascular Disseminada/epidemiologia , Coagulação Intravascular Disseminada/complicações , Feminino , Pessoa de Meia-Idade , Leucemia Mieloide Aguda/complicações , Leucemia Mieloide Aguda/sangue , Idoso , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/sangue , AdultoRESUMO
ABSTRACT: Microclots have been associated with various conditions, including postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. They have been postulated to be amyloid-fibrin(ogen) aggregates, but their role as a prognostic biomarker remains unclear. To examine their possible clinical utility, blood samples were collected for the first 96 hours from critically ill patients (n = 104) admitted to the intensive care unit (ICU). Detection was by staining platelet-poor plasma samples with thioflavin T and visualized by fluorescent microscopy. Image J software was trained to identify and quantify microclots, which were detected in 44 patients (42.3%) on ICU admission but not in the remaining 60 (57.7%) or the 20 healthy controls (0.0%). Microclots on admission to ICU were associated with a primary diagnosis of sepsis (microclots present in sepsis, 23/44 [52.3%] vs microclots absent in sepsis, 19/60 [31.7%]; P = .044). Multicolor immunofluorescence demonstrated that microclots consisted of amyloid-fibrinogen aggregates, which was supported by proteomic analysis. Patients with either a high number or larger-sized microclots had a higher likelihood of developing disseminated intravascular coagulation (odds ratio [OR], 51.4; 95% confidence interval [CI], 6.3-6721.1; P < .001) and had an increased probability of 28-day mortality (OR, 5.3; 95% CI, 2.0-15.6; P < .001). This study concludes that microclots, as defined by amyloid-fibrin(ogen) aggregates, are potentially useful in identifying sepsis and predicting adverse coagulopathic and clinical outcomes.
Assuntos
Amiloide , COVID-19 , Coagulação Intravascular Disseminada , Fibrinogênio , Humanos , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/mortalidade , Coagulação Intravascular Disseminada/etiologia , Coagulação Intravascular Disseminada/diagnóstico , Feminino , Masculino , Pessoa de Meia-Idade , Idoso , Amiloide/metabolismo , Fibrinogênio/análise , Fibrinogênio/metabolismo , COVID-19/sangue , COVID-19/mortalidade , COVID-19/complicações , Sepse/mortalidade , Sepse/sangue , Prognóstico , SARS-CoV-2/isolamento & purificação , Biomarcadores , Agregados Proteicos , Estado TerminalRESUMO
D-dimer, a universally unique marker for fibrin degradation, is generated through the enzymatic interplay of thrombin, factor XIIIa, and plasmin. The emergence of D-dimer-containing fibrin molecules occurs in both intravascular and extravascular spaces during pivotal physiological processes like haemostasis, thrombosis, and tissue repair. Given the inherently physiological nature of fibrin formation and fibrinolysis, basal levels of D-dimer fragments are present in plasma. Beyond its role as a marker of routine physiological processes, aberrations in D-dimer levels are indicative of a spectrum of conditions, both non-pathological and pathological. The clinical utility of D-dimer has been firmly established, particularly in scenarios like venous thromboembolism (VTE), pulmonary embolism (PE), deep vein thrombosis (DVT), and disseminated intravascular coagulation (DIC). Additionally, recent applications have extended to assess the prognosis of COVID-19. While D-dimer is commonly associated with thrombotic conditions, its elevation is not confined to these conditions alone. Elevated D-dimer levels are observed across various diseases, where its significance extends beyond diagnostic indicators to prognostic implications.
Assuntos
Biomarcadores , COVID-19 , Produtos de Degradação da Fibrina e do Fibrinogênio , Humanos , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , COVID-19/sangue , COVID-19/diagnóstico , Biomarcadores/sangue , SARS-CoV-2 , Coagulação Intravascular Disseminada/diagnóstico , Coagulação Intravascular Disseminada/sangue , Fibrinólise , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/sangue , Prognóstico , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/sangue , Trombose Venosa/diagnóstico , Trombose Venosa/sangueRESUMO
Abstract Background and objective Prediction of postoperative excessive blood loss is useful for management of Intensive Care Unit after cardiac surgery. The aim of present study was to examine the effectiveness of International Society on Thrombosis and Hemostasis scoring system in patients with cardiac surgery. Method After obtaining approval from the institutional review board, the medical records of patients undergoing elective cardiac surgery using Cardio-Pulmonary Bypass between March 2010 and February 2014 were retrospectively reviewed. International Society on Thrombosis and Hemostasis score was calculated in intensive care unit and patients were divided with overt disseminated intravascular coagulation group and non-overt disseminated intravascular coagulation group. To evaluate correlation with estimated blood loss, student t-test and correlation analyses were used. Results Among 384 patients with cardiac surgery, 70 patients with overt disseminated intravascular coagulation group (n = 20) or non-overt disseminated intravascular coagulation group (n = 50) were enrolled. Mean disseminated intravascular coagulation scores at intensive care unit admission was 5.35 ± 0.59 (overt disseminated intravascular coagulation group) and 2.66 ± 1.29 (non-overt disseminated intravascular coagulation group) and overt disseminated intravascular coagulation was induced in 29% (20/70). Overt disseminated intravascular coagulation group had much more EBL for 24 h (p = 0.006) and maintained longer time of intubation time (p = 0.005). Conclusion In spite of limitation of retrospective design, management using International Society on Thrombosis and Hemostasis score in patients after cardiac surgery seems to be helpful for prediction of the post- cardio-pulmonary bypass excessive blood loss and prolonged tracheal intubation duration.
Resumo Justificativa e objetivo A previsão de perda sanguínea excessiva no pós-operatório é útil para o manejo em Unidade de Terapia Intensiva (UTI) após cirurgia cardíaca. O objetivo do presente estudo foi examinar a eficácia do sistema de classificação da Sociedade Internacional de Trombose e Hemostasia (International Society on Thrombosis and Hemostasis - ISTH) em pacientes submetidos à cirurgia cardíaca. Método Após obter a aprovação do Comitê de Pesquisa Institucional, os prontuários de pacientes submetidos à cirurgia cardíaca eletiva com circulação extracorpórea (CEC) entre março de 2010 e fevereiro de 2014 foram retrospectivamente revisados. O escore ISTH foi calculado na UTI e os pacientes foram alocados em dois grupos: grupo com coagulação intravascular disseminada (CID) manifesta e grupo com CID não manifesta. Para avaliar a correlação com a Perda Estimada de Sangue (PES), o teste t de Student e as análises de correlação foram usados. Resultados Dentre os 384 pacientes submetidos à cirurgia cardíaca, 70 com CID manifesta (n = 20) ou CID não manifesta (n = 50) foram incluídos. As médias dos escores CID na admissão na UTI foram 5,35 ± 0,59 (Grupo CID manifesta) e 2,66 ± 1,29 (Grupo CID não manifesta) e induzida CID manifesta em 29% (20/70). O grupo CID manifesta apresentou PES superior durante 24 horas (p = 0,006) e um tempo maior de intubação (p = 0,005). Conclusão Apesar da limitação do desenho retrospectivo, o uso do escore ISTH para o manejo de pacientes após cirurgia cardíaca parece ser útil para prever a perda sanguínea excessiva pós-CEC e o prolongamento da intubação traqueal.
Assuntos
Humanos , Masculino , Feminino , Ponte Cardiopulmonar , Hemorragia Pós-Operatória/epidemiologia , Coeficiente Internacional Normatizado , Coagulação Intravascular Disseminada/sangue , Procedimentos Cirúrgicos Cardíacos , Valor Preditivo dos Testes , Estudos RetrospectivosAssuntos
Humanos , Pneumonia Viral/sangue , Síndrome do Desconforto Respiratório do Recém-Nascido/sangue , Infecções por Coronavirus/sangue , Betacoronavirus , Hemostasia/fisiologia , Tempo de Tromboplastina Parcial , Pneumonia Viral/complicações , Tempo de Protrombina , Síndrome do Desconforto Respiratório do Recém-Nascido/etiologia , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Fatores de Risco , Interleucinas/metabolismo , Infecções por Coronavirus , Infecções por Coronavirus/complicações , Fatores de Necrose Tumoral/metabolismo , Coagulação Intravascular Disseminada/sangue , PandemiasRESUMO
Propósito: describir la situación de salud oral de los niños portadores de coagulopatías atendidos en el Servicio de Hemoterapia del Centro Hospitalario Pereira Rossell de Montevideo,Uruguay, entre febrero del 2008 y diciembre del 2009, y compararla con un grupo sin coagulopatías. Método: se realizó un estudio retrospectivo de casos y controles. El grupo deestudio estuvo conformado por 39 pacientes (edad: 8,62 ±4,20 años) y el grupo de control, por 78 (edad: 6,5 ± 2,88 años). El análisis de los hallazgos fue descriptivo. Resultados: enel grupo de niños con coagulopatías se encontró un índice ceo-d 2,85 ± 2,41 y un CPO-d 1,96 ±2,59, ambos ligeramente superiores al grupo control. Según la clasificación de lacoagulopatía se registró: hemofilia A en 17 pacientes, hemofilia B en 7, deficiencia de factor XII en un paciente y enfermedad de von Willebrand en 14. La adherencia al tratamientofue calificada como buena en 15 pacientes, mientras que fue mala en los 24 pacientes restantes. Conclusión: este es un primer reporte de salud oral en niños con coagulopatías en Uruguay. Es necesario hacer un seguimiento y aumentar la cobertura de este programa para mantener la salud oral de estos pacientes...
Aim: Describe the oral health status of children with inherited bleeding disorders who attended the Pereira Rossell Hospital in Montevideo Uruguay for dental care, between February 2008 and December 2009, and compare it with children without bleeding disorders. Methods:A retrospective case-control study was carried out. The study group consisted of 39 patients (age: 8.62 ± 4.20 years), while the control group had 78 patients (age 6.5 ± 2.88). Descriptive analysis was done to the data. Results: The study group had a dmf-s index 2.85± 2.41 and a DMF-s 1.96 ± 2.59, being slightly higher than in the control group. The bleeding disorder classification was: Hemophilia A, 17 patients; Hemophilia B, 7 patients; factor XII deficit, 1 patient; and Von Willebrand disease, 14 patients. Commitment to the treatmentwas determined as good in 15 patients and bad in 24 patients. Conclusion: This is the first oral health report on children with bleeding disorders from this program in Uruguay. It isnecessary to follow up the patients and increase the program coverage in order to maintain the oral health of this kind of patients...
Assuntos
Criança , Assistência Odontológica para Crianças/enfermagem , Assistência Odontológica para Crianças/métodos , Coagulação Intravascular Disseminada/congênito , Coagulação Intravascular Disseminada/diagnóstico , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/terapia , Odontopediatria/classificação , UruguaiAssuntos
Humanos , Plasma , Transfusão de Componentes Sanguíneos/normas , Manejo de Espécimes , Transtornos da Coagulação Sanguínea , Argentina , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/terapia , Criopreservação/normas , Doenças de von Willebrand/sangue , Doenças de von Willebrand/terapia , Hepatopatias/sangue , Hepatopatias/terapia , Púrpura Trombocitopênica Trombótica/sangue , Púrpura Trombocitopênica Trombótica/terapiaAssuntos
Humanos , Plasma , Transfusão de Componentes Sanguíneos/normas , Argentina , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/terapia , Criopreservação/normas , Doenças de von Willebrand/sangue , Doenças de von Willebrand/terapia , Hepatopatias/sangue , Hepatopatias/terapia , Manejo de Espécimes/normas , Púrpura Trombocitopênica Trombótica/sangue , Púrpura Trombocitopênica Trombótica/terapia , Transtornos da Coagulação Sanguínea/sangue , Transtornos da Coagulação Sanguínea/terapiaRESUMO
O uso de método funcional para dosagem de antitrombina III (ATIII) é fundamental para o diagnóstico de deficiência deste inibidor da coagulaçao. OBJETIVO. Padronizar metodologia para dosagem da ATIII no plasma, utilizando-se microplacas, em diferentes situaçoes clínicas. MÉTODOS. A dosagem de ATIII foi feita utilizando-se o substrato cromogênico Tos-Gly-Pro-Arg-NAN, específico para trombina, e sintetizado no Departamento de Biofísica da Escola Paulista de Medicina. RESULTADOS. Dos 21 pacientes com trombose venosa (TV-P), 20 apresentaram valores superiores a 70 por cento (ll3 ñ 22 por cento), dos quais uma paciente de 22 anos apresentava deficiência congênita, com ATIII de 56 por cento e história de TVP recorrente, além de história familiar de TVP. O nível de ATIII em seis pacientes portadores de doença de von Willebrand foi normal (lO9 ñ 28 por cento), como esperado. Em 20 pacientes com insuficiência hepática foi observada reduçao importante do nível de ATIII (42 ñ 19 por cento), pois este inibidor é produzido no hepatócito, sendo bom parâmetro para avaliar a funçao hepática. Os três pacientes portadores de sepse com CIVD apresentaram níveis reduzidos de ATIII (45 + 5 por cento), que é consumida durante processo de ativaçao intravascular da coagulaçao. Os níveis de ATIII mostraram correlaçao significante com o TP e os níveis de fator V, ambos bons parâmetros para avaliaçao da funçao hepática e para monitorizaçao da CIVD. Houve correlaçao significante entre as dosagens realizadas com o substrato Tos-Gly-Pro-Arg-NAN, sintetizado na EPM, e o substrato S-2238 do laboratório Kabi. CONCLUSOES. A medida da ATIII usando substrato cromogênico Gly-Pro-Arg-NAN é de fácil execuçao e é sensível para o diagnóstico da deficiência deste inibidor em pacientes com insuficiência heopática, coagulaçao intravascular disseminada e trombofilia.